Jay T. Evans, Ph.D.
President and Chief Executive Officer
Dr. Evans is the President, Chief Executive Officer and Co-Founder of Inimmune Corp. Dr. Evans is also Director of the Center for Translational Medicine at the University of Montana and a Research Professor in the Division of Biological Sciences. He has over 20 years’ experience in the biotechnology and pharmaceutical industry including 15 years at GlaxoSmithKline Vaccines (formerly Corixa Corporation) where he held various roles including North American Pre-Clinical Innovation Team Leader, Project Leader, and Investigator. Dr. Evans completed his Postdoctoral Fellowship at the University of Texas Southwestern Medical Center and St. Jude Children’s Research Hospital working in HIV immunology, stem cell transplantation, and vector-based gene therapy systems. Dr. Evans holds a Ph.D. in Molecular and Cellular Biology from Oregon State University and a B.S. in Biology from Pacific Lutheran University.
David J. Burkhart, Ph.D.
Chief Operating Officer
Dr. David Burkhart is the Chief Operating Officer and Co-Founder of Inimmune, while also overseeing the formulation science R&D team. Dr. Burkhart was an investigator with GlaxoSmithKline for nearly 8 years leading the formulation R&D team where he demonstrated a knack for innovation and project/team management which led to his promotion from his starting role as a Principal Scientist. Prior to his work with GSK, Dr. Burkhart was a Senior Scientist with the CMO Hollister-Stier labs in Spokane, Washington for two years where he gained invaluable experience in cGMP analytical and manufacturing. He has over 10 years of experience in the biotechnology and pharmaceutical industries with experience in project management, leadership, business development, and licensing with over 13 years experience in medicinal and analytical chemistry, formulation and drug delivery. David earned his Ph.D. in organic chemistry in 2002 from the University of Idaho and conducted research in oncology as a postdoctoral scientist at the University of Colorado, Boulder until 2005.
Helene Bazin-Lee, Ph.D
Vice President, Early Discovery
Dr. Bazin-Lee is VP, Early Discovery and Co-Founder of Inimmune, serving as head of early discovery research programs. She has over 17 years of experience in the biotech and pharmaceutical industries including 14 years with Corixa/GlaxoSmithKline developing new synthetic immunomodulators and vaccine adjuvants, managing medicinal chemistry efforts and new adjuvant discovery projects. Dr. Bazin-Lee earned an M.Sc. in Chemical Engineering at the ENSCCF (France) and received her Ph.D. in Organic Chemistry from the University of Lyon I (France). She then completed a postdoctoral fellowship at the University of Iowa, focusing on the development of new synthetic methods for the synthesis of glycosaminoglycan building blocks. Dr. Bazin-Lee is a co-inventor on 15 patents.
Kendal Ryter, Ph.D.
Vice President, Manufacturing and Dev.
Dr. Ryter is VP, Manufacturing and Development and Co-Founder of Inimmune. He started his postgraduate synthetic career working at Albany Molecular Research, Inc. In Albany NY. The experience highlighted his ability to adapt and come up to speed quickly on new projects and classes of drug pharmacophores. From alkaloids to opiates to complex heterocycles he worked on projects that included drug discovery and SAR to development and cGMP production, including work in 50-100 L reactors and supervision of pilot plant production. The opportunity to join Corixa was seen as a new challenge and he delivered as project lead on the development to commercial production of a late-stage, novel TLR4 agonist. Continuing his efforts at GSK, he adapted and contributed to the basic understanding of vaccine adjuvant mechanism of action, developed new methods for preparing complex molecules at scale and seamlessly transitioned projects to contract manufacture. With >18 years of industrial experience, he now leads Product Development at Inimmune.
VP of Legal and Business Strategy
Before joining Inimmune, Mr. Conger served as Assistant General Counsel-Patents for GlaxoSmithKline (GSK), advising leaders of research programs for fourteen years, including a close association with the scientists who would later found Inimmune. Prior to GSK, Mr. Conger worked five years in private practice at a large, regional firm in Salt Lake City. Mr. Conger is a skilled lead patent counsel, having managed intellectual property issues arising from university, industry, and government-sponsored research programs in the United States, Canada, Europe, and Asia. Mr. Conger earned his Juris Doctorate degree from Brigham Young University Law School and a Bachelor of Science degree from the BYU College of Biology.